SLC5A2 and diabetic ketoacidosis: A benefit over the use of medications like SGLT-2 inhibitors (used off-label by individuals with T1D to lower postprandial glucose spikes), this investigational medication is much less likely to result in diabetic ketoacidosis, even with less circulating insulin present and a lower risk of hypoglycemia.